Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 20/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 14/20 | 0.71 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | APLNR | P35414 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | GLP1R | P43220 | 1/20 | 0.49 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4675775 | 1.00 | GNRHR (0.71) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL14607453 | 0.90 | GNRHR (0.59) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL4674691 | 0.90 | GNRHR (0.87) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL4674695 | 0.90 | GNRHR (0.87) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL24295417 | 0.88 | GNRHR (0.71) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL4028649 | 0.86 | GNRHR (0.64) | GNRHRCYP3A4 | |
| SCHEMBL4032101 | 0.83 | GNRHR (0.78) | GNRHRCYP3A4 | |
| SCHEMBL4032104 | 0.83 | GNRHR (0.78) | GNRHRCYP3A4 | |
| SCHEMBL4022522 | 0.83 | GNRHR (0.78) | GNRHRCYP3A4 | |
| SCHEMBL1378029 | 0.83 | GNRHR (1.00) | GNRHRCYP3A4ADRB2APLNROPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1646389-B1 | PYRIMIDINE-2,4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES INC (US) | 2008-09-10 | — | — | EP | claimed |
| US-7176211-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-02-13 | — | — | US | claimed |
| US-20060122202-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-06-08 | — | — | US | claimed |
| US-7056927-B2 | 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1H,3H)-dione; utility in treatment of a variety of sex-hormone related conditions in both men and women | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-06-06 | — | — | US | claimed |
| US-20050038057-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (CA) | 2005-02-17 | — | — | US | claimed |
| EP-1646389-B1 | PYRIMIDINE-2,4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES INC (US) | 2008-09-10 | — | — | EP | disclosed |
| US-7419983-B2 | e.g. 3-[{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,3H)-dione; sex-hormone related diseases; anticarcinogenic agent; endometriosis, uterine fibroids, polycystic ovarian disease | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20070191403-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-7056927-B2 | 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1H,3H)-dione; utility in treatment of a variety of sex-hormone related conditions in both men and women | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20050038057-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (CA) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191403-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | GNRHR 1/4885CYP3A4 1565/4885ADRB2 406/4885 |
| US-20060122202-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | GNRHR 1/4885CYP3A4 1565/4885ADRB2 406/4885 |
| US-20050038057-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | GNRHR 1/4885CYP3A4 1565/4885ADRB2 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.